KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will host an expert physician panel discussion during an ancillary event at the 67th American Society of Hematology (ASH) ...

Core Insights - Caribou Biosciences Inc. reported significant advancements in its CAR-T therapy, showing complete and durable remissions in patients with advanced B-cell lymphoma [1][3] - The company’s stock surged by 17.56% following the announcement of positive trial results [6] Group 1: CAR-T Therapy Results - In the ongoing ANTLER phase 1 trial, 64% of patients achieved a complete response, while the overall response rate was 82% [3] - At one year, the progression-free survival rate was 51%, indicating that patients remained alive without cancer worsening [3] - The efficacy and durability of vispacel are comparable to autologous CAR-T cell therapies, based on data from a cohort of 35 patients [3] Group 2: Safety and Regulatory Insights - The therapy demonstrated a generally well-tolerated safety profile across all 84 patients treated in the ANTLER trial [4] - The FDA has recommended a randomized, controlled trial for second-line large B-cell lymphoma patients who are ineligible for transplant and autologous CAR-T therapy [4] - The company plans to conduct a pivotal phase 3 trial evaluating approximately 250 patients [4] Group 3: CB-011 Clinical Data - Caribou shared initial clinical data from the CaMMouflage Phase 1 trial of CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy, showing a 92% overall response rate and a 75% complete response rate [5][6] - 91% of patients achieved minimal residual disease negativity, indicating no detectable cancer cells [6] - The company plans to advance the CB-011 program into dose expansion by the end of this year, with data expected in 2026 [5]

Core Insights - Caribou Biosciences, Inc. will present new data from the ANTLER phase 1 clinical trial for vispacabtagene regedleucel (vispa-cel) and the CaMMouflage Phase 1 trial for CB-011 on November 3, 2025 [1] - The company is focused on developing allogeneic CAR-T cell therapies for hematologic malignancies, specifically targeting relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma [1][5] Summary of vispacabtagene regedleucel (vispa-cel) - Vispacabtagene regedleucel is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma [3] - It is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, aimed at enhancing CAR-T cell activity by reducing premature exhaustion [3] - The therapy has received FDA designations including Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track for B-NHL [3] Summary of CB-011 - CB-011 is an allogeneic anti-BCMA CAR-T cell therapy being evaluated for relapsed or refractory multiple myeloma in the CaMMouflage Phase 1 trial [4] - It is the first allogeneic CAR-T cell therapy engineered with an immune cloaking strategy, featuring a B2M knockout and a B2M–HLA-E fusion protein to mitigate immune rejection [4] - CB-011 has also been granted Fast Track and Orphan Drug designations by the FDA [4] Company Overview - Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on transformative therapies for severe diseases [5] - The company's genome-editing platform utilizes Cas12a chRDNA technology for precise development of cell therapies [5] - Caribou aims to provide broad access and rapid treatment options through its off-the-shelf CAR-T cell therapies, vispacabtagene regedleucel and CB-011 [5]

Core Insights - Caribou Biosciences, Inc. will present new data from the ANTLER phase 1 clinical trial for vispacabtagene regedleucel (vispa-cel) and the CaMMouflage Phase 1 trial for CB-011 on November 3, 2025 [1] - The company is focused on developing allogeneic CAR-T cell therapies for hematologic malignancies, specifically targeting relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma [5] Group 1: Clinical Trials - The ANTLER trial evaluates vispacabtagene regedleucel (vispa-cel), an allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma [3] - The CaMMouflage trial assesses CB-011, an allogeneic anti-BCMA CAR-T cell therapy for patients with relapsed or refractory multiple myeloma [4] - Both therapies have received Fast Track and Orphan Drug designations from the FDA, indicating their potential significance in treating these conditions [3][4] Group 2: Technology and Innovation - Vispacabtagene regedleucel (vispa-cel) is noted for being the first allogeneic CAR-T cell therapy with a PD-1 knockout, aimed at enhancing CAR-T cell activity [3] - CB-011 is distinguished as the first allogeneic CAR-T cell therapy utilizing an immune cloaking strategy with a B2M knockout and B2M–HLA-E fusion protein [4] - Caribou's genome-editing platform employs Cas12a chRDNA technology, which allows for superior precision in developing cell therapies [5]

Core Insights - Caribou Biosciences, Inc. is a leading clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for patients with severe diseases [3] - The company will have its president and CEO, Rachel Haurwitz, participate in a fireside chat at the Citi 2025 Biopharma Back to School Conference on September 3, 2025 [1] Company Overview - Caribou's genome-editing platform utilizes Cas12a chRDNA technology, which allows for superior precision in developing cell therapies [3] - The company is concentrating on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies aimed at providing broad access and rapid treatment for patients with hematologic malignancies [3] Event Information - A webcast of the fireside chat will be available on Caribou's website for at least 30 days following the event [2]

Core Insights - Caribou Biosciences, Inc. is advancing its allogeneic CAR-T cell programs, CB-010 and CB-011, with robust clinical datasets expected to be disclosed in the second half of 2025 [1][2] - The company reported $184 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into the second half of 2027 [1][4] Clinical Programs - CB-010 is an allogeneic anti-CD19 CAR-T cell therapy targeting B cell non-Hodgkin lymphoma, while CB-011 is an anti-BCMA CAR-T cell therapy for multiple myeloma [3][11][12] - Both programs are generating encouraging Phase 1 results, reinforcing the potential of these therapies [2] Financial Performance - As of June 30, 2025, Caribou had $183.9 million in cash, down from $249.4 million at the end of 2024 [4][17] - Licensing and collaboration revenue for Q2 2025 was $2.7 million, a decrease from $3.5 million in Q2 2024 [5][18] - Research and development expenses were $27.7 million for Q2 2025, down from $35.5 million in the same period last year [5][18] Losses and Expenses - The company reported a net loss of $54.1 million, or $0.58 per share, for Q2 2025, compared to a net loss of $37.7 million, or $0.42 per share, for Q2 2024 [9][18] - Non-GAAP net loss for Q2 2025, excluding non-cash impairment charges, was $32.8 million, or $0.35 per share [9][19] Strategic Updates - Caribou is interacting with the FDA regarding a potential pivotal trial for CB-010, contingent on positive data and alignment [5][6] - The company plans to present data from both clinical trials in H2 2025, which will include initial safety and efficacy data [5][6]

Company Overview - Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for patients with severe diseases [3] - The company's genome-editing platform utilizes Cas12a chRDNA technology, which offers superior precision for developing cell therapies [3] - Caribou is concentrating on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies aimed at providing broad access and rapid treatment for patients with hematologic malignancies [3] Upcoming Events - Rachel Haurwitz, PhD, the president and CEO of Caribou, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4 at 9:20 AM EDT [1] - A link to the webcast of the event will be available on Caribou's website, and the webcasts will remain accessible for at least 30 days post-event [2]

Company Overview - Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for patients with severe diseases [3] - The company's genome-editing platform utilizes Cas12a chRDNA technology, which offers superior precision for developing cell therapies aimed at improving activity against diseases [3] Product Focus - Caribou is concentrating on two off-the-shelf CAR-T cell therapies, CB-010 and CB-011, which have the potential to provide broad access and rapid treatment for patients suffering from hematologic malignancies [3] Upcoming Events - Rachel Haurwitz, PhD, the president and CEO of Caribou, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT [1] - Webcasts of the event will be available on Caribou's website for at least 30 days following the event [2]

Core Insights - Caribou Biosciences is strategically prioritizing its lead oncology programs, CB-010 and CB-011, while implementing workforce and cost reduction initiatives to extend its cash runway into H2 2027 [1][13] - The company plans to disclose robust clinical datasets for CB-010 and CB-011 in H2 2025, which are expected to demonstrate efficacy in treating hematologic malignancies [2][14] Pipeline Prioritization - Caribou is focusing resources on CB-010 and CB-011, discontinuing the GALLOP Phase 1 trial for lupus and the AMpLify Phase 1 trial for acute myeloid leukemia [5][7] - The workforce reduction is approximately 32%, with expected cash savings of $2.5 to $3.5 million from these strategic decisions [13] Clinical Programs - CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for B cell non-Hodgkin lymphoma, with data expected to show outcomes comparable to approved autologous CAR-T therapies [6][10] - CB-011 is an allogeneic anti-BCMA CAR-T cell therapy for multiple myeloma, with ongoing dose escalation trials showing encouraging efficacy [4][11] Financial Position - As of March 31, 2025, Caribou expects to report $212.5 million in cash, cash equivalents, and marketable securities [8] - The strategic changes are anticipated to extend the company's cash runway by one year, allowing operations to continue into H2 2027 [13] Upcoming Milestones - In H2 2025, Caribou plans to present data from the ANTLER Phase 1 trial for CB-010, including safety and efficacy data from a 20-patient cohort [14] - For CB-011, the company will present dose escalation data and recommended doses for expansion from the ongoing CaMMouflage Phase 1 trial [14]